OpenAlex
PricingAboutJobs
Log inGet started
Work

Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab-refractory breast cancer model

HTML

Year: 2013
Type: article
Source: Cancer Chemotherapy and Pharmacology
DOI: 10.1007/s00280-013-2233-7
Authors: Yuliang Sun, Nandini Dey, Melissa Brammer, Pradip De, Brian Leyland-Jones
Institutions: University of South Dakota, Sanford Research, Genentech
Language: English

Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: bevacizumab, trastuzumab, pertuzumab, HER2-positive breast cancer, trastuzumab emtansine, anti-angiogenic therapy, PIK3CA mutation, Akt phosphorylation, ERK1/2 phosphorylation, triple combination therapy, tumor growth inhibition
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2005408316
FWCI: 1.271
Cites: 26
Cited by: 9
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms